TNFRSF10A and non-small cell lung carcinoma: Blocking the expression of DR5 but not expression of DR4 using small interfering RNA has been shown to make cells less susceptible to apoptosis caused by a combination of bortezomib with TRAIL in human Non-small-cell lung carcinoma (NSCLC) cells [28].